Squalene,
does it really help with Skin and immunity?
research showsDirect human efficacy RCTs for oral squalene on skin and immunity are not confirmed. Safety and immunogenicity data for vaccine adjuvants such as MF59, or cosmetic squalane safety data, are safety/formulation data in those contexts and are not evidence for the skin or immune efficacy of oral squalene supplements. Because the ingredient and use context should not be confused, this is kept as Judgment deferred.
ads claimAdvertisements mention "shark liver oil," "immunity," "skin glow," and "antioxidant" together. The fact that it is a vaccine adjuvant or a sebum component should be separated from clinical effects of oral supplements.
Useful facts when choosing a product
- Squalene can be obtained from shark liver oil, olives, amaranth, and other sources.
- Shark-derived ingredients have separate issues involving marine contaminants, allergy, and sustainability.
- Squalane is a hydrogenated cosmetic ingredient and is distinguished from oral squalene.
- Long-term high-dose oral safety data are limited.
What the research actually shows
Spanova 2011 and similar literature summarize squalene biosynthesis and uses. O'Hagan 2013 and WHO/EMA materials deal with immunogenicity and safety contexts for squalene-based vaccine adjuvants such as MF59. Cosmetic safety assessments address topical safety of squalene/squalane but are not RCTs of skin improvement from oral supplements. In particular, squalane is a hydrogenated cosmetic ingredient and differs from oral squalene in ingredient and use context. Shark liver oil products contain other components such as alkylglycerols in addition to squalene, making it difficult to isolate the single-ingredient effect.
Why this is classified as ?
Direct human efficacy RCTs for oral squalene on skin and immunity are not confirmed, and MF59 vaccine-adjuvant safety/immunogenicity data and cosmetic squalane safety data are not efficacy evidence, so this is kept as Judgment deferred.
Counterpoint. Vaccine-adjuvant safety is not evidence of oral supplement efficacy.
Rejudgment record. Draft — Direct human efficacy RCTs for oral squalene on skin and immunity are not confirmed; MF59 vaccine-adjuvant and cosmetic squalane materials are not efficacy evidence
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Spanova M & Daum G 2011 | Narrative literature review | Academic | Squalene biochemistry and uses | Reviewed squalene biosynthesis, biology, and applications. | Background | |
| O'Hagan DT et al. 2013 | Vaccine-adjuvant review | 59 | Mixed industry/academic | Vaccine immunogenicity and safety | Summarized evidence on squalene emulsion adjuvants, but not oral supplement efficacy. | Separate |
| Cosmetic Ingredient Review 1982/2019 | Cosmetic safety assessment | Industry/regulatory-related | Topical safety | Assessed the safety of squalene/squalane at cosmetic concentrations. | Safety |
Receipt — 4 References
Every cited source was opened and checked against the live page on 2026-07-10.
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-10 · Corrections: none
Cite this verdict
[Chamgap] Squalene x skin and immunity — Evidence Grade ?. 4 cited sources checked. Source: https://health-receipt.pages.dev/en/verdicts/skin-hair/squalene-skin-immunity/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.